Search Antibody Database

Found 1 matching record:

Displaying record number 4154

Download this epitope record as JSON.

MAb ID	CAP256-VRC26.25LS (VRC26.25LS)
HXB2 Location	gp160	gp160 Epitope Map
Author Location	gp160
Epitope
Subtype	C
Ab Type	gp120 V2 // V2 glycan(V2g) // V2 apex
Neutralizing	P (tier2)
Species (Isotype)	human
Patient	CAP256
Immunogen	engineered
Keywords	antibody generation, broad neutralizer, immunoprophylaxis, immunotherapy, neutralization, structure

Notes

Showing 2 of 2 notes.

CAP256: This study used LC-MS to define the glycosylation, disulfide bonding, and other post-transcriptional modifications of CAP256-VRC26.25-LS. The mAb was found to be susceptible to clipping in the CDRH3 region, at the L117-Q118 site. Ivleva2018 (structure)
CAP256-VRC26.25-LS: The mAb CAP256-VRC26.25 was engineered with the Fc-LS mutation to increase its half-life, and this modified mAb was named CAP256-VRC26.25-LS. Two mAbs (CAP256-VRC26.25-LS and PGDM1400) were assessed against a novel SHIV challenge stock, SHIV-325c. This SHIV was created in order to be more susceptible to neutralization than other SHIV stocks, in order better model human HIV infection in macaques. Macaques received an infusion of either CAP256-VRC26.25-LS or PGDM1400 prior to challenge with SHIV-325c. PGDM1400 was fully protective at an intermediate dose, whereas CAP256-VRC26.25-LS was fully protective even at the lowest dose given. Julg2017a (antibody generation, immunoprophylaxis, neutralization, immunotherapy, broad neutralizer)

References

Showing 2 of 2 references.

Isolation Paper
Julg2017a Boris Julg, Lawrence J. Tartaglia, Brandon F. Keele, Kshitij Wagh, Amarendra Pegu, Devin Sok, Peter Abbink, Stephen D. Schmidt, Keyun Wang, Xuejun Chen, M. G. Joyce, Ivelin S. Georgiev, Misook Choe, Peter D. Kwong, Nicole A. Doria-Rose, Khoa Le, Mark K. Louder, Robert T. Bailer, Penny L. Moore, Bette Korber, Michael S. Seaman, Salim S. Abdool Karim, Lynn Morris, Richard A. Koup, John R. Mascola, Dennis R. Burton, and Dan H. Barouch. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med, 9(406):9/406/eaal1321 doi, Sep 2017. PubMed ID: 28878010 Show all entries for this paper.

Ivleva2018 Vera B. Ivleva, Nicole A. Schneck, Deepika Gollapudi, Frank Arnold, Jonathan W. Cooper, and Q. Paula Lei. Investigation of Sequence Clipping and Structural Heterogeneity of an HIV Broadly Neutralizing Antibody by a Comprehensive LC-MS Analysis. J Am Soc Mass Spectrom, 29(7):1512-1523 doi, Jul 2018. PubMed ID: 29736600 Show all entries for this paper.